Industry: Service & Software
Published Date: 2026-07-17
Pages: 200 Pages
Report ld: 6977458
Request Sample
Customized Report
Plasma Proteomics Service Market Size(US$)

CAGR 2026-2032
12.2%
Market Size,2032
USD 1,474
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Plasma Proteomics Service market size was US$ 668 million in 2025 and is forecast to reach a readjusted size of US$ 1474 million by 2032 with a CAGR of 12.2% during the forecast period 2026-2032.
Plasma Proteomics Service refers to specialized research services that use human or animal plasma samples as the primary biological material and apply advanced proteomics technologies to systematically identify, quantify, and interpret circulating proteins, protein abundance changes, functional alterations, and disease-associated molecular signatures.
As a critical liquid biological sample, plasma contains extensive protein information released from multiple tissues, organs, and immune systems. Changes in plasma protein profiles can reflect physiological conditions, disease progression, and therapeutic responses. Compared with tissue proteomics, plasma proteomics offers advantages including minimally invasive sampling, repeatability, and suitability for large-scale clinical cohort studies. Compared with genomics and transcriptomics, plasma proteomics directly measures functional molecules closer to biological phenotypes.
Plasma Proteomics Services typically integrate liquid chromatography tandem mass spectrometry (LC-MS/MS), data-independent acquisition (DIA), tandem mass tag labeling (TMT), parallel reaction monitoring (PRM), proximity extension assays (PEA), and aptamer-based proteomics technologies. Combined with artificial intelligence, bioinformatics, and multi-omics analysis, these services provide complete workflows covering plasma sample preparation, protein profiling, quantitative analysis, biomarker discovery, and biological pathway interpretation.
Plasma Proteomics Services are widely applied in oncology, immunotherapy research, cardiovascular disease, neurodegenerative disorders, autoimmune diseases, metabolic diseases, and pharmaceutical development. Companies including Olink, SomaLogic, Seer, and Biognosys have developed large-scale plasma proteomic analysis platforms. Olink Explore enables high-throughput profiling of thousands of plasma proteins and is widely used in population studies and drug discovery research.
Plasma Proteomics Services primarily operate under a technology-intensive life science CRO model combining advanced analytical platforms, specialized laboratory expertise, and bioinformatics capabilities.
Unlike conventional laboratory testing, plasma proteomics integrates protein chemistry, mass spectrometry, computational biology, artificial intelligence, and disease biology interpretation. Service providers typically establish high-resolution mass spectrometry platforms, automated sample preparation systems, multiplex protein profiling platforms, and computational pipelines to provide customized plasma proteomics solutions.
Typical workflows include research design, plasma sample receiving and quality control, protein extraction, depletion or enrichment of abundant proteins, enzymatic digestion, mass spectrometry or affinity-based detection, quality control, protein quantification, differential analysis, biomarker discovery, pathway analysis, and scientific reporting.
The value chain includes upstream suppliers of mass spectrometry instruments, chromatography systems, protein detection reagents, antibodies, aptamer technologies, bioinformatics software, and laboratory consumables. The midstream sector consists of proteomics CRO providers, multi-omics platforms, and clinical research organizations. Downstream customers include pharmaceutical companies, biotechnology firms, hospitals, biobanks, and precision medicine organizations.
Plasma Proteomics Services represent a high-value-added segment with attractive profitability. Standardized plasma profiling services generally achieve gross margins of approximately 45%-65%. Advanced services involving deep mass spectrometry, DIA proteomics, large clinical cohorts, and pharmaceutical research typically achieve margins of 60%-80% due to higher technological complexity and data value.
Plasma Proteomics Services are becoming important technology infrastructure for precision medicine, innovative drug discovery, and clinical translation.
As life science research moves from gene expression analysis toward functional protein biology, demand for circulating biomarkers, disease prediction models, and therapeutic response evaluation continues to increase. Plasma samples offer accessibility, clinical relevance, and scalability for large population studies, making plasma proteomics one of the most commercially mature areas within proteomics.
The expansion of biobanks, AI-assisted analysis, multi-omics integration, and precision medicine continues to accelerate market growth. Plasma proteomics enables large-scale analysis of circulating protein changes, creating new opportunities in cancer screening, immunotherapy, neurological research, and drug mechanism studies. High-throughput platforms such as Olink and SomaLogic have been widely adopted in population studies and pharmaceutical research, accelerating the commercialization of plasma proteomics.
Plasma Proteomics Services face challenges including the extremely broad dynamic range of plasma proteins, difficulty detecting low-abundance biomarkers, workflow standardization issues, and complex data interpretation.
High-abundance plasma proteins may interfere with biomarker discovery, requiring advanced depletion strategies, highly sensitive analytical platforms, and computational approaches. Platform comparability, clinical validation timelines, and regulatory requirements will influence future commercialization.
Future demand for Plasma Proteomics Services will increasingly focus on pharmaceutical development, clinical research, population-scale studies, and companion diagnostics.
Pharmaceutical companies will utilize plasma proteomics for target discovery, mechanism-of-action studies, patient stratification, and clinical trial optimization. Biotechnology companies will increasingly rely on specialized CRO providers to reduce infrastructure investment and accelerate innovation. Research institutions and hospitals will expand applications in oncology, cardiovascular disease, neurological disorders, and immune-related diseases.
With the continued growth of precision medicine and data-driven biology, Plasma Proteomics Service providers with high-throughput platforms, advanced analytics, proprietary databases, and global delivery capabilities will become strategic partners across the life science ecosystem.
The global Plasma Proteomics Service market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
MARKET SEGMENTATION
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Plasma Proteomics Service value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Discovery Plasma Proteomics
1.2.3 DIA Plasma Proteomics
1.2.4 TMT Plasma Proteomics
1.2.5 Targeted Plasma Proteomics
1.2.6 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Disease Biomarker Research
1.3.3 Drug Development
1.3.4 Clinical Research
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Plasma Proteomics Service Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Plasma Proteomics Service Market Share by Revenue, by Region (2021-2026)
2.4 Global Plasma Proteomics Service Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.2 Europe Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.3 China Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.4 Japan Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.5 Southeast Asia Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.6 India Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.7 South America Plasma Proteomics Service Market Size and Prospective (2021-2032)
2.5.8 Middle East Plasma Proteomics Service Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Plasma Proteomics Service Historical Market Size by Type (2021-2026)
3.2 Global Plasma Proteomics Service Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Plasma Proteomics Service
4 Breakdown Data by Application
4.1 Global Plasma Proteomics Service Historical Market Size by Application (2021-2026)
4.2 Global Plasma Proteomics Service Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Plasma Proteomics Service Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Plasma Proteomics Service Players by Revenue (2021-2026)
5.1.2 Global Plasma Proteomics Service Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Plasma Proteomics Service Revenue
5.4 Global Plasma Proteomics Service Market Concentration Analysis
5.4.1 Global Plasma Proteomics Service Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Plasma Proteomics Service Revenue in 2025
5.5 Global Key Players of Plasma Proteomics Service Head Offices and Areas Served
5.6 Global Key Players of Plasma Proteomics Service, Product and Application
5.7 Global Key Players of Plasma Proteomics Service, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Plasma Proteomics Service Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Plasma Proteomics Service Market Size by Type (2021-2026)
6.1.2.2 North America Plasma Proteomics Service Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Plasma Proteomics Service Market Size by Application (2021-2026)
6.1.3.2 North America Plasma Proteomics Service Market Share by Application (2021-2026)
6.1.4 North America Plasma Proteomics Service Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Plasma Proteomics Service Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Plasma Proteomics Service Market Size by Type (2021-2026)
6.2.2.2 Europe Plasma Proteomics Service Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Plasma Proteomics Service Market Size by Application (2021-2026)
6.2.3.2 Europe Plasma Proteomics Service Market Share by Application (2021-2026)
6.2.4 Europe Plasma Proteomics Service Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Plasma Proteomics Service Revenue by Company (2021-2026)
6.3.2 China Market Size by Type
6.3.2.1 China Plasma Proteomics Service Market Size by Type (2021-2026)
6.3.2.2 China Plasma Proteomics Service Market Share by Type (2021-2026)
6.3.3 China Market Size by Application
6.3.3.1 China Plasma Proteomics Service Market Size by Application (2021-2026)
6.3.3.2 China Plasma Proteomics Service Market Share by Application (2021-2026)
6.3.4 China Plasma Proteomics Service Major Customers
6.3.5 China Market Trends and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Plasma Proteomics Service Revenue by Company (2021-2026)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Plasma Proteomics Service Market Size by Type (2021-2026)
6.4.2.2 Japan Plasma Proteomics Service Market Share by Type (2021-2026)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Plasma Proteomics Service Market Size by Application (2021-2026)
6.4.3.2 Japan Plasma Proteomics Service Market Share by Application (2021-2026)
6.4.4 Japan Plasma Proteomics Service Major Customers
6.4.5 Japan Market Trends and Opportunities
6.5 Southeast Asia Market: Players, Segments, Downstream and Major Customers
6.5.1 Southeast Asia Plasma Proteomics Service Revenue by Company (2021-2026)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Plasma Proteomics Service Market Size by Type (2021-2026)
6.5.2.2 Southeast Asia Plasma Proteomics Service Market Share by Type (2021-2026)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Plasma Proteomics Service Market Size by Application (2021-2026)
6.5.3.2 Southeast Asia Plasma Proteomics Service Market Share by Application (2021-2026)
6.5.4 Southeast Asia Plasma Proteomics Service Major Customers
6.5.5 Southeast Asia Market Trends and Opportunities
6.6 India Market: Players, Segments, Downstream and Major Customers
6.6.1 India Plasma Proteomics Service Revenue by Company (2021-2026)
6.6.2 India Market Size by Type
6.6.2.1 India Plasma Proteomics Service Market Size by Type (2021-2026)
6.6.2.2 India Plasma Proteomics Service Market Share by Type (2021-2026)
6.6.3 India Market Size by Application
6.6.3.1 India Plasma Proteomics Service Market Size by Application (2021-2026)
6.6.3.2 India Plasma Proteomics Service Market Share by Application (2021-2026)
6.6.4 India Plasma Proteomics Service Major Customers
6.6.5 India Market Trends and Opportunities
7 Key Player Profiles
7.1 Olink (Thermo Fisher Scientific)
7.1.1 Olink (Thermo Fisher Scientific) Company Details
7.1.2 Olink (Thermo Fisher Scientific) Business Overview
7.1.3 Olink (Thermo Fisher Scientific) Plasma Proteomics Service Introduction
7.1.4 Olink (Thermo Fisher Scientific) Revenue in Plasma Proteomics Service Business (2021-2026)
7.1.5 Olink (Thermo Fisher Scientific) Recent Development
7.2 SomaLogic (Illumina)
7.2.1 SomaLogic (Illumina) Company Details
7.2.2 SomaLogic (Illumina) Business Overview
7.2.3 SomaLogic (Illumina) Plasma Proteomics Service Introduction
7.2.4 SomaLogic (Illumina) Revenue in Plasma Proteomics Service Business (2021-2026)
7.2.5 SomaLogic (Illumina) Recent Development
7.3 Labcorp
7.3.1 Labcorp Company Details
7.3.2 Labcorp Business Overview
7.3.3 Labcorp Plasma Proteomics Service Introduction
7.3.4 Labcorp Revenue in Plasma Proteomics Service Business (2021-2026)
7.3.5 Labcorp Recent Development
7.4 BostonGene
7.4.1 BostonGene Company Details
7.4.2 BostonGene Business Overview
7.4.3 BostonGene Plasma Proteomics Service Introduction
7.4.4 BostonGene Revenue in Plasma Proteomics Service Business (2021-2026)
7.4.5 BostonGene Recent Development
7.5 CellCarta
7.5.1 CellCarta Company Details
7.5.2 CellCarta Business Overview
7.5.3 CellCarta Plasma Proteomics Service Introduction
7.5.4 CellCarta Revenue in Plasma Proteomics Service Business (2021-2026)
7.5.5 CellCarta Recent Development
7.6 GENEWIZ (Azenta Life Sciences)
7.6.1 GENEWIZ (Azenta Life Sciences) Company Details
7.6.2 GENEWIZ (Azenta Life Sciences) Business Overview
7.6.3 GENEWIZ (Azenta Life Sciences) Plasma Proteomics Service Introduction
7.6.4 GENEWIZ (Azenta Life Sciences) Revenue in Plasma Proteomics Service Business (2021-2026)
7.6.5 GENEWIZ (Azenta Life Sciences) Recent Development
7.7 CDI Labs
7.7.1 CDI Labs Company Details
7.7.2 CDI Labs Business Overview
7.7.3 CDI Labs Plasma Proteomics Service Introduction
7.7.4 CDI Labs Revenue in Plasma Proteomics Service Business (2021-2026)
7.7.5 CDI Labs Recent Development
7.8 Biognosys
7.8.1 Biognosys Company Details
7.8.2 Biognosys Business Overview
7.8.3 Biognosys Plasma Proteomics Service Introduction
7.8.4 Biognosys Revenue in Plasma Proteomics Service Business (2021-2026)
7.8.5 Biognosys Recent Development
7.9 Discovery Life Sciences
7.9.1 Discovery Life Sciences Company Details
7.9.2 Discovery Life Sciences Business Overview
7.9.3 Discovery Life Sciences Plasma Proteomics Service Introduction
7.9.4 Discovery Life Sciences Revenue in Plasma Proteomics Service Business (2021-2026)
7.9.5 Discovery Life Sciences Recent Development
7.10 Firalis Molecular Precision
7.10.1 Firalis Molecular Precision Company Details
7.10.2 Firalis Molecular Precision Business Overview
7.10.3 Firalis Molecular Precision Plasma Proteomics Service Introduction
7.10.4 Firalis Molecular Precision Revenue in Plasma Proteomics Service Business (2021-2026)
7.10.5 Firalis Molecular Precision Recent Development
7.11 Cell Signaling Technology (CST)
7.11.1 Cell Signaling Technology (CST) Company Details
7.11.2 Cell Signaling Technology (CST) Business Overview
7.11.3 Cell Signaling Technology (CST) Plasma Proteomics Service Introduction
7.11.4 Cell Signaling Technology (CST) Revenue in Plasma Proteomics Service Business (2021-2026)
7.11.5 Cell Signaling Technology (CST) Recent Development
7.12 Sampled (Infinity Biologix)
7.12.1 Sampled (Infinity Biologix) Company Details
7.12.2 Sampled (Infinity Biologix) Business Overview
7.12.3 Sampled (Infinity Biologix) Plasma Proteomics Service Introduction
7.12.4 Sampled (Infinity Biologix) Revenue in Plasma Proteomics Service Business (2021-2026)
7.12.5 Sampled (Infinity Biologix) Recent Development
7.13 APTBIO
7.13.1 APTBIO Company Details
7.13.2 APTBIO Business Overview
7.13.3 APTBIO Plasma Proteomics Service Introduction
7.13.4 APTBIO Revenue in Plasma Proteomics Service Business (2021-2026)
7.13.5 APTBIO Recent Development
7.14 Sinotech Genomics
7.14.1 Sinotech Genomics Company Details
7.14.2 Sinotech Genomics Business Overview
7.14.3 Sinotech Genomics Plasma Proteomics Service Introduction
7.14.4 Sinotech Genomics Revenue in Plasma Proteomics Service Business (2021-2026)
7.14.5 Sinotech Genomics Recent Development
7.15 Biodesix
7.15.1 Biodesix Company Details
7.15.2 Biodesix Business Overview
7.15.3 Biodesix Plasma Proteomics Service Introduction
7.15.4 Biodesix Revenue in Plasma Proteomics Service Business (2021-2026)
7.15.5 Biodesix Recent Development
7.16 Panome Bio
7.16.1 Panome Bio Company Details
7.16.2 Panome Bio Business Overview
7.16.3 Panome Bio Plasma Proteomics Service Introduction
7.16.4 Panome Bio Revenue in Plasma Proteomics Service Business (2021-2026)
7.16.5 Panome Bio Recent Development
7.17 Novogene
7.17.1 Novogene Company Details
7.17.2 Novogene Business Overview
7.17.3 Novogene Plasma Proteomics Service Introduction
7.17.4 Novogene Revenue in Plasma Proteomics Service Business (2021-2026)
7.17.5 Novogene Recent Development
7.18 PTM BIO
7.18.1 PTM BIO Company Details
7.18.2 PTM BIO Business Overview
7.18.3 PTM BIO Plasma Proteomics Service Introduction
7.18.4 PTM BIO Revenue in Plasma Proteomics Service Business (2021-2026)
7.18.5 PTM BIO Recent Development
7.19 BGI Genomics
7.19.1 BGI Genomics Company Details
7.19.2 BGI Genomics Business Overview
7.19.3 BGI Genomics Plasma Proteomics Service Introduction
7.19.4 BGI Genomics Revenue in Plasma Proteomics Service Business (2021-2026)
7.19.5 BGI Genomics Recent Development
7.20 Evotec
7.20.1 Evotec Company Details
7.20.2 Evotec Business Overview
7.20.3 Evotec Plasma Proteomics Service Introduction
7.20.4 Evotec Revenue in Plasma Proteomics Service Business (2021-2026)
7.20.5 Evotec Recent Development
7.21 Metware Biotechnology
7.21.1 Metware Biotechnology Company Details
7.21.2 Metware Biotechnology Business Overview
7.21.3 Metware Biotechnology Plasma Proteomics Service Introduction
7.21.4 Metware Biotechnology Revenue in Plasma Proteomics Service Business (2021-2026)
7.21.5 Metware Biotechnology Recent Development
7.22 MRM Proteomics
7.22.1 MRM Proteomics Company Details
7.22.2 MRM Proteomics Business Overview
7.22.3 MRM Proteomics Plasma Proteomics Service Introduction
7.22.4 MRM Proteomics Revenue in Plasma Proteomics Service Business (2021-2026)
7.22.5 MRM Proteomics Recent Development
7.23 Lc-Bio Technologies
7.23.1 Lc-Bio Technologies Company Details
7.23.2 Lc-Bio Technologies Business Overview
7.23.3 Lc-Bio Technologies Plasma Proteomics Service Introduction
7.23.4 Lc-Bio Technologies Revenue in Plasma Proteomics Service Business (2021-2026)
7.23.5 Lc-Bio Technologies Recent Development
7.24 Eurofins Scientific
7.24.1 Eurofins Scientific Company Details
7.24.2 Eurofins Scientific Business Overview
7.24.3 Eurofins Scientific Plasma Proteomics Service Introduction
7.24.4 Eurofins Scientific Revenue in Plasma Proteomics Service Business (2021-2026)
7.24.5 Eurofins Scientific Recent Development
7.25 MtoZ-Biolabs
7.25.1 MtoZ-Biolabs Company Details
7.25.2 MtoZ-Biolabs Business Overview
7.25.3 MtoZ-Biolabs Plasma Proteomics Service Introduction
7.25.4 MtoZ-Biolabs Revenue in Plasma Proteomics Service Business (2021-2026)
7.25.5 MtoZ-Biolabs Recent Development
7.26 Creative Proteomics
7.26.1 Creative Proteomics Company Details
7.26.2 Creative Proteomics Business Overview
7.26.3 Creative Proteomics Plasma Proteomics Service Introduction
7.26.4 Creative Proteomics Revenue in Plasma Proteomics Service Business (2021-2026)
7.26.5 Creative Proteomics Recent Development
7.27 Macrogen
7.27.1 Macrogen Company Details
7.27.2 Macrogen Business Overview
7.27.3 Macrogen Plasma Proteomics Service Introduction
7.27.4 Macrogen Revenue in Plasma Proteomics Service Business (2021-2026)
7.27.5 Macrogen Recent Development
7.28 TATAA Biocenter
7.28.1 TATAA Biocenter Company Details
7.28.2 TATAA Biocenter Business Overview
7.28.3 TATAA Biocenter Plasma Proteomics Service Introduction
7.28.4 TATAA Biocenter Revenue in Plasma Proteomics Service Business (2021-2026)
7.28.5 TATAA Biocenter Recent Development
7.29 OmicScouts (Momentum Biotechnologies)
7.29.1 OmicScouts (Momentum Biotechnologies) Company Details
7.29.2 OmicScouts (Momentum Biotechnologies) Business Overview
7.29.3 OmicScouts (Momentum Biotechnologies) Plasma Proteomics Service Introduction
7.29.4 OmicScouts (Momentum Biotechnologies) Revenue in Plasma Proteomics Service Business (2021-2026)
7.29.5 OmicScouts (Momentum Biotechnologies) Recent Development
7.30 Precision Biomarker Laboratories (PBL)
7.30.1 Precision Biomarker Laboratories (PBL) Company Details
7.30.2 Precision Biomarker Laboratories (PBL) Business Overview
7.30.3 Precision Biomarker Laboratories (PBL) Plasma Proteomics Service Introduction
7.30.4 Precision Biomarker Laboratories (PBL) Revenue in Plasma Proteomics Service Business (2021-2026)
7.30.5 Precision Biomarker Laboratories (PBL) Recent Development
7.31 Shanghai OE Biotech
7.31.1 Shanghai OE Biotech Company Details
7.31.2 Shanghai OE Biotech Business Overview
7.31.3 Shanghai OE Biotech Plasma Proteomics Service Introduction
7.31.4 Shanghai OE Biotech Revenue in Plasma Proteomics Service Business (2021-2026)
7.31.5 Shanghai OE Biotech Recent Development
7.32 RxCelerate
7.32.1 RxCelerate Company Details
7.32.2 RxCelerate Business Overview
7.32.3 RxCelerate Plasma Proteomics Service Introduction
7.32.4 RxCelerate Revenue in Plasma Proteomics Service Business (2021-2026)
7.32.5 RxCelerate Recent Development
7.33 Proteomics International
7.33.1 Proteomics International Company Details
7.33.2 Proteomics International Business Overview
7.33.3 Proteomics International Plasma Proteomics Service Introduction
7.33.4 Proteomics International Revenue in Plasma Proteomics Service Business (2021-2026)
7.33.5 Proteomics International Recent Development
7.34 Proteome Sciences
7.34.1 Proteome Sciences Company Details
7.34.2 Proteome Sciences Business Overview
7.34.3 Proteome Sciences Plasma Proteomics Service Introduction
7.34.4 Proteome Sciences Revenue in Plasma Proteomics Service Business (2021-2026)
7.34.5 Proteome Sciences Recent Development
7.35 Westlake Omics
7.35.1 Westlake Omics Company Details
7.35.2 Westlake Omics Business Overview
7.35.3 Westlake Omics Plasma Proteomics Service Introduction
7.35.4 Westlake Omics Revenue in Plasma Proteomics Service Business (2021-2026)
7.35.5 Westlake Omics Recent Development
7.36 Crown Bioscience
7.36.1 Crown Bioscience Company Details
7.36.2 Crown Bioscience Business Overview
7.36.3 Crown Bioscience Plasma Proteomics Service Introduction
7.36.4 Crown Bioscience Revenue in Plasma Proteomics Service Business (2021-2026)
7.36.5 Crown Bioscience Recent Development
7.37 VProteomics
7.37.1 VProteomics Company Details
7.37.2 VProteomics Business Overview
7.37.3 VProteomics Plasma Proteomics Service Introduction
7.37.4 VProteomics Revenue in Plasma Proteomics Service Business (2021-2026)
7.37.5 VProteomics Recent Development
7.38 Shanghai Majorbio Bio-Pharm
7.38.1 Shanghai Majorbio Bio-Pharm Company Details
7.38.2 Shanghai Majorbio Bio-Pharm Business Overview
7.38.3 Shanghai Majorbio Bio-Pharm Plasma Proteomics Service Introduction
7.38.4 Shanghai Majorbio Bio-Pharm Revenue in Plasma Proteomics Service Business (2021-2026)
7.38.5 Shanghai Majorbio Bio-Pharm Recent Development
7.39 Applied Biomics
7.39.1 Applied Biomics Company Details
7.39.2 Applied Biomics Business Overview
7.39.3 Applied Biomics Plasma Proteomics Service Introduction
7.39.4 Applied Biomics Revenue in Plasma Proteomics Service Business (2021-2026)
7.39.5 Applied Biomics Recent Development
7.40 Sapient Bioanalytics
7.40.1 Sapient Bioanalytics Company Details
7.40.2 Sapient Bioanalytics Business Overview
7.40.3 Sapient Bioanalytics Plasma Proteomics Service Introduction
7.40.4 Sapient Bioanalytics Revenue in Plasma Proteomics Service Business (2021-2026)
7.40.5 Sapient Bioanalytics Recent Development
8 Plasma Proteomics Service Market Dynamics
8.1 Plasma Proteomics Service Industry Trends
8.2 Plasma Proteomics Service Market Drivers
8.3 Plasma Proteomics Service Market Challenges
8.4 Plasma Proteomics Service Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
The global Plasma Proteomics Service market was valued at US$ 668 million in 2025 and is anticipated to reach US$ 1474 million by 2032, at a CAGR of 12.2% from 2026 to 2032.
Published Date: 2026-07-17
Pages: 183
USD 2900.00
(Single User License)
The global market for Plasma Proteomics Service was estimated to be worth US$ 668 million in 2025 and is projected to reach US$ 1474 million, growing at a CAGR of 12.2% from 2026 to 2032.
Published Date: 2026-07-17
Pages: 191
USD 3950.00
(Single User License)
The global Plasma Proteomics Service market is projected to grow from US$ 668 million in 2025 to US$ 1474 million by 2032, at a CAGR of 12.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-07-17
Pages: 216
USD 4900.00
(Single User License)
The global Plasma Proteomics Service market was valued at US$ 668 million in 2025 and is anticipated to reach US$ 1474 million by 2032, at a CAGR of 12.2% from 2026 to 2032.
Published: 2026-07-17
Pages: 183
The global market for Plasma Proteomics Service was estimated to be worth US$ 668 million in 2025 and is projected to reach US$ 1474 million, growing at a CAGR of 12.2% from 2026 to 2032.
Published: 2026-07-17
Pages: 191
The global Plasma Proteomics Service market is projected to grow from US$ 668 million in 2025 to US$ 1474 million by 2032, at a CAGR of 12.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-07-17
Pages: 216
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now